Abstract
Subanesthetic ketamine rapidly and robustly reduces depressive symptoms in patients with treatment-resistant depression. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of ketamine in depression may be opioid dependent. Using pharmacological functional ultrasound imaging in rats, we found that blocking opioid receptors suppressed neurophysiologic changes evoked by ketamine, but not by a more selective NMDAR antagonist, in regions implicated in the pathophysiology of depression and in reward processing. Importantly, this opioid-dependent response was strongly sex dependent, as it was not evident in female subjects and was fully reversed by surgical removal of the male gonads. We observed similar opioid-mediated sex-dependent effects in ketamine-evoked structural plasticity and behavioral sensitization. Together, these results underscore the potential for ketamine to induce its affective responses via opioid signaling, and indicate that this opioid dependence may be strongly influenced by subject sex. These factors should be more directly assessed in future clinical trials.
One-Sentence Summary Subanesthetic ketamine evokes opioid-mediated behavioral and neurophysiological effects in male, but not female, rats.
Competing Interest Statement
RDA has equity and has received consulting fees from Cordance Medical and Lumos Labs and grant funding from AbbVie Inc. MM has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences, Inc. TDI has equity/stock options and receives consulting fees from Attune Neurosciences, Inc. All other authors declare no conflicts of interest.